Search results
Results from the WOW.Com Content Network
The Regeneron International Science and Engineering Fair (ISEF) is an annual science fair in the United States. [1] It is owned and administered by the Society for Science, [2] a 501(c)(3) non-profit organization based in Washington, D.C. [3] Each May, more than 1800 students from roughly 75 countries and territories compete in the fair for scholarships, tuition grants, internships, scientific ...
The Regeneron Science Talent Search, known for its first 57 years [1] as the Westinghouse Science Talent Search, and then as the Intel Science Talent Search (Intel STS) from 1998 through 2016, [2] is a research-based science competition in the United States for high school seniors.
The Regeneron International Science and Engineering Fair, or ISEF, is the largest high school STEM competition in the world. • Saathvik Kannan received one of two Regeneron Young Scientist ...
1 The Regeneron International Science and Engineering Fair (ISEF) is an annual science fair in the United States.[1] It is owned and administered by the Society for Science,[2] a 501(c)(3) non-profit organization based in Washington, D.C.[3] Each May, more than 1500 students from roughly 70 countries and territories compete in the fair for scholarships, tuition grants, internships, scientific ...
The Intel Foundation Achievement Awards are US$5,000 scholarships presented to high school students in recognition of their achievements in the scientific disciplines. Up to 15 are awarded, on selection by a panel of judges, each year at the Intel International Science and Engineering Fair (ISEF).
Amaze Award: This award is given to a team with a consistently high-performing robot. An engineering notebook is not required for this award, but the team should be able to explain how they worked together to build and design their robot. Build Award: This award is given to a team with a sturdy, safe, and reliable robot. This is often given to ...
The FDA has accepted Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering ...
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo